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OBJECTIVE — Adiponectin,ahormonesecretedbyadiposetissue,isofparticularinterestin
metabolic syndrome, because it is inversely correlated with obesity and insulin sensitivity.
However, it is not known to what extent the genetics of plasma adiponectin and the genetics of
obesity and insulin sensitivity are interrelated. We aimed to evaluate the heritability of plasma
adiponectin and its genetic correlation with the metabolic syndrome and metabolic syndrome–
related traits and the association between these traits and 10 ADIPOQ single nucleotide poly-
morphisms (SNPs).
RESEARCH DESIGN AND METHODS — We made use of a family-based population,
the Erasmus Rucphen Family study (1,258 women and 967 men). Heritability analysis was
performed using a polygenic model. Genetic correlations were estimated using bivariate herita-
bility analyses. Genetic association analysis was performed using a mixed model.
RESULTS — Plasma adiponectin showed a heritability of 55.1%. Genetic correlations be-
tween plasma adiponectin HDL cholesterol and plasma insulin ranged from 15 to 24% but were
not signiﬁcant for fasting glucose, triglycerides, blood pressure, homeostasis model assessment
of insulin resistance (HOMA-IR), and C-reactive protein. A signiﬁcant association with plasma
adiponectin was found for ADIPOQ variants rs17300539 and rs182052. A nominally signiﬁcant
associationwasfoundwithplasmainsulinandHOMA-IRandADIPOQvariantrs17300539after
adjustment for plasma adiponectin.
CONCLUSIONS — The signiﬁcant genetic correlation between plasma adiponectin and
HDL cholesterol and plasma insulin should be taken into account in the interpretation of
genome-wide association studies. Association of ADIPOQ SNPs with plasma adiponectin was
replicated, and we showed association between one ADIPOQ SNP and plasma insulin and
HOMA-IR.
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T
he dramatic increase in the preva-
lence of the metabolic syndrome in
countries with a western lifestyle is
precipitated by environmental variables.
However, the individual susceptibility to
the obesogenic environment is largely de-
termined by genetic susceptibility (1).
Central obesity, dyslipidemia, impaired
glucose metabolism, and hypertension
are the key elements determining the ex-
pression of the metabolic syndrome (2),
which is associated with an increased risk
fortype2diabetesandcardiovasculardis-
ease (2).
Adipose tissue is an active endocrine
tissuethatcanrespondtochangesinmet-
abolicconditionsbysecretingbiologically
active substances (adipokines). The adi-
pokine family can be divided into two
overlapping sets of signaling molecules,
namely those with metabolic/immuno-
logical function, which include interleu-
kins 1, 6, 8, 10, or 18, tumor necrosis
factor- and transforming growth fac-
tor-,andthosewithendocrinefunction,
which include leptin, retinol-binding
protein 4, adiponectin, and resistin (3).
Human adiponectin is a protein of 247
amino acids (30-kDa), encoded by a gene
(ADIPOQ) located on chromosome 3q27
(4). Adiponectin is secreted and present
inplasmainvariousmultimericforms,for
which the biological signiﬁcance remains
to be determined. Rasmussen-Torvik et
al.(5)showedthatbindingofadiponectin
to adiponectin receptors (ADIPOR1 and
ADIPOR2) in mice results in increased
AMP-activatedproteinkinaseactivityand
peroxisome proliferator–activated recep-
tor- activity. In humans, both receptors
are expressed mainly in skeletal muscle
and adiponectin could thus play a role in
energy metabolism.
Theroleofadiponectininenergyme-
tabolism is conﬁrmed by its inverse cor-
relation with body weight, metabolic
syndrome, metabolic syndrome–related
traits, and type 2 diabetes (6). In mouse
models, adiponectin has been shown to
play a role in energy homeostasis by reg-
ulating insulin sensitivity of the liver (7).
In addition, adiponectin is suggested to
exhibit anti-inﬂammatory properties (8).
Thus, adiponectin could play a role in
obesity–induced impairment of the met-
abolic state, systemic inﬂammation, and
the corresponding risk for cardiovascular
disease.
Limited data on the overall heritabil-
ity of plasma adiponectin are available.
Furthermore,itisnotknownwhetherthe
genetics of plasma adiponectin overlap
with the genetics of body weight and in-
sulinsensitivity/diabetesorotherindivid-
ual components of the metabolic
syndrome. Several studies showed con-
vincing association of genetic variants
near and in the promoter region of the
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and type 2 diabetes or type 2 diabetes–
related traits (5,9,10).
In the present study, we set out to
evaluate the heritability of plasma adi-
ponectin and its genetic correlation with
the metabolic syndrome and metabolic
syndrome–related traits (BMI, insulin,
homeostasis model assessment of insulin
resistance [HOMA-IR], and plasma C-
reactive protein [CRP]).
RESEARCH DESIGN AND
METHODS— In the present study,
we used data of the Erasmus Rucphen
Family (ERF) study, which is embedded
into a rural genetically isolated popula-
tion (Genetic Research in Isolated Popu-
lations [GRIP]). This young, genetic
isolate from the southwest Netherlands
was initiated by 400 founders in the
middle of 18th century. Minimal immi-
gration occurred among the surrounding
settlements for social and religious rea-
sons. The population experienced a fast
expansion and at the moment this region
includes roughly 20,000 inhabitants. The
ERFpopulationisacross-sectionalcohort
and includes 3,000 individuals who were
not selected based on health information
but rather comprise living descendants of
22 couples who had at least six children
baptized in the community church in ap-
proximately 1850–1900. Details about
thegenealogyofthepopulationhavebeen
published elsewhere (11,12). In the cur-
rentstudy,weincluded2,256individuals
of the ERF population for whom all study
parameters were known. We did not ex-
clude participants based on health status.
The study protocol was approved by the
medical ethics board of the Erasmus MC
Rotterdam (Rotterdam, Netherlands). All
investigations were carried out in accor-
dance with the Declaration of Helsinki.
Data collection
Blood from participants was obtained in a
fasted state. Total plasma insulin mea-
surements were analyzed with an INS-
IRMA kit (BioSource), total plasma
adiponectin with a human adiponectin
RIAkit(LincoResearch),andtotalplasma
CRP with a CRP ELISA (Diagnostic Sys-
tems Laboratories). All measurements
were performed to conform to the manu-
facturer’s protocol. Insulin sensitivity was
based on the HOMA-IR) (glucose insu-
lin/22.5). Plasma CRP showed kurtosis;
therefore, upper plasma CRP levels ex-
ceeding three times the SD of the mean
wereremovedfromfurtheranalyses.Data
on plasma adiponectin, insulin, HOMA-
IR, and CRP were available for 2,256 in-
dividuals. Metabolic syndrome was
assessed according to the criteria of the
International Diabetes Federation (2006,
Europids), which requires a minimum
waist circumference and two of the fol-
lowingabnormalities:highfastingplasma
glucose, low HDL cholesterol, high total
plasma triglycerides, and high systolic
(SBP) and/or diastolic blood pressure
(DBP),describedindetailinsupplementary
Table 1 (available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-1385/DC1). Prevalence
and heritability of the metabolic syndrome
and related traits in the ERF have been re-
ported previously (1,13).
Statistical analyses
Analysis of mean differences between
groupswastestedusingANOVAstatistics
(continuous variables) or 
2 statistics
(categorical variables). Correlations of
plasma adiponectin with other traits were
estimated in men and women separately
with adjustment for age and BMI. Herita-
bility estimations were obtained using
SOLAR software (version 2.05; http://
solar.sfbrgenetics.org)(1,11).Heritability
andgeneticassociationanalyseswereper-
formed using normal log-transformed
traitvaluesandthe“tdist”functioninSO-
LAR. The polygenic model (covariates:
sex and age) was applied. Heritability es-
timations included a second variance
component,thesibshipeffect,whichisan
estimate of phenotypic similarity, due to
effects of a shared (early) environment
and genetically dominant effects (1). The
effect of relevant medication use was as-
sumed to be covered by the metabolic
syndrome deﬁnition (model B). Inbreed-
ing coefﬁcients in heritability estimations
were not signiﬁcant and therefore were
excluded from further analyses. To deter-
mine the genetic correlations of plasma
adiponectin with other traits we used
bivariate heritability analysis. We also
estimated sex-speciﬁc heritability using
bivariateanalysisoftraitsstratiﬁedbysex.
Because the latter analysis is conﬁned to
one quantitative trait, the environmental
correlation component is forced to be
zero. Bivariate analysis was applied to
plasma adiponectin with the metabolic
syndrome components and metabolic
syndrome–relatedcomponentsusingsex,
age, and BMI as covariates (model A) or
using sex, age, and metabolic syndrome
ascovariates(modelB).Thebivariateher-
itability analysis yields estimates of the
total overlapping genetic and environ-
mental component (correlation) of these
traits.
The following ADIPOQ variants were
selected after literature review (9) and
conﬁrmed for tag property using Haplov-
iew (r
2  0.8; minor allele frequency
10%) and CEU HapMap data:
rs864265, rs822387, rs17300539
(11391G/A), rs266729, rs182052,
rs822396, rs2241766 (45T/G),
rs1501299 (276G/T), rs3774262, and
rs6773957. Selected variants were geno-
typed using a Sequenom iPLEX applica-
tion (matrix-assisted laser desorption
ionization/time of ﬂight; Sequenom, San
Diego, CA). Genotypes were screened for
Mendelian errors using the pedigree
structure (14). All 10 ADIPOQ variants
achieved a call rate of 95% and all were
in Hardy-Weinberg equilibrium (P 
0.05). For ADIPOQ genotype association,
we assumed an additive model. Analysis
of plasma adiponectin included the co-
variates sex, age, and BMI (model A) or
covariates sex, age, and metabolic syn-
drome (model B). To investigate whether
ADIPOQ single nucleotide polymor-
phisms (SNPs) were independently asso-
ciated with plasma adiponectin, we
applied a backward linear regression
modelcontainingallSNPsthatwereasso-
ciated with plasma adiponectin at a false
discovery rate 0.05. The following
model was used: rs822387, rs17300539,
rs182052, rs1501299, rs6773957, sex,
age, and BMI as independent variables
and plasma adiponectin as the dependent
variable. The independence of the associ-
ated SNPs was conﬁrmed in Haploview,
and these SNPs were used in association
analysis with the metabolic syndrome–
related traits.
Association analyses of ADIPOQ vari-
ants with metabolic syndrome–related
traits was performed using two models
with different covariates: 1) sex, age, and
BMIand2)sex,age,BMI,andplasmaadi-
ponectin.Adjustmentforfamilystructure
of the association model was based on a
pedigree matrix obtained using Illumina
6K linkage chip data. Analysis was per-
formed using model residuals in a score
test accounting for pedigree structure as
implemented in GenABEL software (15)
function “mmscore” (16). The Bayesian
information criterion (BIC) for plasma
adiponectin was implemented on associ-
ated ADIPOQ SNPs, sex, age, and BMI us-
ing R software. All other analyses were
performed using SPSS 14.01 (September
2005; SSPS, Chicago, IL) software.
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ERF cohort are presented in Table 1. The
prevalence of the metabolic syndrome,
according to the International Diabetes
Federation deﬁnition, was 29.3% in
women and 37.1% in men. Virtually all
mean values differed signiﬁcantly (P 
0.01) between sexes.
To determine the association of
plasma adiponectin with the metabolic
syndrome and related traits, we calcu-
lated partial correlation coefﬁcients of
plasma adiponectin with each trait stud-
ied (supplementary Table 2, available in
an online appendix) adjusted for age and
BMI. Plasma adiponectin showed a high
correlation with the metabolic syndrome
(	
 0.20 and 	
 0.13 in women
and men, respectively) and with the lipid
components HDL cholesterol and triglyc-
erides (all 	  0.15, P  0.01). The cor-
relation of plasma adiponectin with BMI
(adjustment only for age), fasting plasma
insulin, HOMA-IR, and plasma CRP
showed correlations coefﬁcients ranging
from 0.10 to 0.29 (all P  0.05). In men,
weobserved,ingeneral,lowercorrelation
coefﬁcients for all components, with the
exception of DBP.
We next estimated the heritability of
plasma adiponectin and metabolic syn-
drome–related traits. Heritability esti-
mates of the metabolic syndrome and its
individual components and BMI in the
ERF were described earlier (1,13). All
heritability estimates were highly signiﬁ-
cant and none of the metabolic syndro-
me–related traits showed a signiﬁcant
sibshipeffectestimate(S).Theheritability
estimate of plasma insulin was 21.4%,
SEM 
 5.2%, P  10
05 (S 
 6.1%,
SEM 
 4.2%, P 
 0.07), of HOMA-IR
was22.0%,SEM
5.3%,P10
05(S

5.8%, SEM 
 4.3%, P 
 0.08), and of
plasma CRP level was 21.0%, SEM 

4.9%, P  10
05 (S 
 nil). The highest
heritabilityestimatewasfoundforplasma
adiponectin: 55.1%, SEM 
 4.7, P 
10
6 (S 
 nil).
Next,weperformedbivariateanalysis
of sex-stratiﬁed age-adjusted traits. We
observed no signiﬁcant difference in the
heritabilitybetweenthesexesandfounda
high correlation (	
100%) between the
heritability of plasma adiponectin in men
(h
2 
 59.6%, SEM 
 9.4) and women
(h
2
52.9%,SEM
7.7).Detailsonsex-
speciﬁc heritability of plasma insulin,
HOMA-IR,andplasmaCRParepresented
detailinsupplementaryTable3(available
in an online appendix). Sex-stratiﬁed bi-
variate heritability estimates of the meta-
bolic syndrome and its individual
components and BMI were described ear-
lier (1,13).
Bivariate heritability analyses were
performed using trait-by-trait analyses on
plasma adiponectin combined with the
metabolic syndrome and metabolic syn-
drome–related traits. To investigate
whether the interrelation between the
traits affected their genetic correlations,
we used two statistical models: model A
included BMI as the covariate and model
Bincludedmetabolicsyndromeastheco-
variate in addition to age and sex in the
trait-by-trait analyses. The outcomes of
the bivariate heritability analysis of
plasma adiponectin and the metabolic
syndrome and the metabolic syndrome
related traits are presented in Table 2.
AccordingtomodelA,metabolicsyn-
drome, waist circumference, and HDL
cholesterol demonstrated a signiﬁcant
(P  10
3) shared genetic component
with plasma adiponectin (42.7, 32.4,
and 24.7%, respectively). Triglycer-
ides,fastingplasmaglucose,andbothSBP
and DBP showed a low and insigniﬁcant
shared genetic component with plasma
adiponectin. BMI and plasma insulin
showed a signiﬁcant (P  0.04) shared
genetic component with plasma adi-
ponectin of, respectively, 32.4 and
20.0%, whereas our ﬁnding for
HOMA-IR was borderline signiﬁcant (ge-
netic correlation [	G] 
 18.6%, P 

0.06). The genetic correlation of plasma
adiponectin and plasma CRP was found
to be not signiﬁcant. The environmental
correlations of plasma adiponectin with
plasma glucose (12.0%), HDL choles-
terol (35.6%), triglycerides (26.0%),
and plasma CRP (13.4%) exceeded
their shared genetic component value. In
contrast,thegeneticcorrelationofplasma
adiponectinandmetabolicsyndromewas
twice as high as their environmental cor-
relation (	G 
 42.7% and environmen-
tal correlation [	E] 
 19.4%).
AccordingtomodelB(covariatessex,age,
and metabolic syndrome), HDL choles-
terol shared a signiﬁcant (15.2%, P 
0.05) genetic component with plasma
adiponectin. Plasma insulin shared a bor-
derlinesigniﬁcant(19.1%,P
0.056)ge-
netic component with plasma
adiponectin. All observed environmental
correlations obtained according to model
B exceeded their genetic correlations (Ta-
ble 2).
To investigate to what extent the high
heritability of plasma adiponectin is due
to variants located in the ADIPOQ gene,
we performed genetic association analy-
sis. Table 3 presents association of 10
ADIPOQ SNPs with plasma adiponectin,
adjusted for sex, age, and BMI (model A)
Table 1—Characteristics of the ERF population
Women Men
n 1,258 967
Age (years) 48.0  14.3 49.4  14.1*
Range (years)/minimum–maximum 68.0/18–86 68.5/18–86
Metabolic syndrome and its individual components
Metabolic syndrome 369 (29.3) 359 (37.1)†
Waist circumference (cm) 81.9  12.0 94.2  11.5†
Glucose (mmol/l) 4.4  0.9 4.8  1.0†
HDL cholesterol (mmol/l) 1.4  0.4 1.1  0.3†
Triglycerides (mmol/l) 1.2  0.7 1.5  0.9†
SBP (mmHg) 136.1  21.2 143.4  18.0†
DBP (mmHg) 78.6  9.8 81.7  9.8†
Metabolic syndrome–related traits
BMI (kg/m
2) 26.6  5.0 27.3  4.1†
Insulin (U/ml) 12.8  5.8 13.9  8.8*
HOMA-IR 2.6  1.6 3.0  2.4†
Adiponectin (mg/l) 12.4  5.8 8.1  4.1†
CRP (mg/l) 11.1  22.2 10.0  28.5†
Medication
Glucose-lowering 26 (2.1) 27 (2.8)
Lipid-lowering 132 (10.5) 144 (14.9)*
Antihypertension 237 (18.8) 201 (20.8)
Data are means  SD for continuous traits and n (%) for categorical traits. *Signiﬁcantly different from
women(P0.05).†P0.01,continuoustraitsbasedonANOVAandnoncategoricaltraitsbasedon
2test.
Shared heritability of adiponectin and the metabolic syndrome
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syndrome (model B). According to both
models A and B, nominally signiﬁcant as-
sociations with plasma adiponectin were
found for two promoter SNPs (rs822387
and rs17300539), one SNP located in
exon 1 (rs182052), one SNP locate in
exon 2 (rs1501299), and one SNP
(rs6773957) located in the 3
-untrans-
lated region of the ADIPOQ gene. Four of
these SNPs (except rs822396 and
rs1501299) remained signiﬁcant after
conservative Bonferroni correction (P 
0.005). The effect size of the promoter
SNPswassubstantiallyhigherthanthatof
the other signiﬁcantly associated SNPs.
To determine the best model explain-
ing plasma adiponectin we used the BIC
(17). The parameters used in the BIC
analysis for plasma adiponectin were sex,
age, BMI, and the ADIPOQ SNPs
rs822387, rs17300539, rs182052,
rs1501299, and rs6773957 (n 
 1,914).
BIC values are presented in supplemen-
taryTable4(availableinanonlineappen-
dix). The lowest BIC value was found for
the model including four ADIPOQ SNPs
(rs822387, rs17300539, rs182052, and
rs6773957).
Backwardlinearregressionanalysisof
the ﬁve associated SNPs indicated that
rs17300539andrs182052wereindepen-
dently associated with plasma adiponec-
tin (P  0.001 and P  0.004,
respectively, in the joint model). Evalua-
tion of r
2 between SNPs using Haploview
conﬁrmed the independence of the two
ADIPOQSNPs(r
2
0.2,plotnotshown).
Next,weanalyzedwhetherthetwosignif-
icant SNPs, ADIPOQ rs17300539 and
rs182052, were also associated with the
metabolic syndrome and metabolic syn-
drome–related traits using two models.
The ﬁrst model included sex, age, and
BMI as covariates. The second model in-
cluded sex, age, BMI, and plasma adi-
ponectin as covariates. The second model
wasusedtoinvestigatewhethermetabolic
syndrome–related traits were associated
independently of plasma adiponectin. No
signiﬁcant associations were found for
rs182052. ADIPOQ rs17300539 showed
a signiﬁcant association with plasma in-
sulin (n 
 1919, 
0.072, SEM 

0.031, P 
 0.022) and with HOMA-IR
(n 
 1,892, 
0.084, SEM 
 0.036,
P 
 0.021), according to model 2.
CONCLUSIONS — Here we report a
high heritability of plasma adiponectin
(55.1%)andasimilargeneticarchitecture
between men and women. We also dem-
onstrated that the genetic component of
the HDL cholesterol and plasma insulin
overlapsigniﬁcantlywiththatofplasma
adiponectin. ADIPOQ rs17300539 and
rs182052 were both found to contrib-
ute independently to the heritability of
plasma adiponectin. Of these two SNPs,
rs17300539 was also associated with
plasma insulin and HOMA-IR, illustrat-
ing their genetic overlap with
adiponectin.
Our estimate of the heritability of
plasma adiponectin is similar to heritabil-
ity (62%) reported by Patel et al. (18).
Furthermore, our heritability estimates
for the metabolic syndrome-related traits
(plasma insulin, HOMA-IR, and plasma
CRP)areinagreementwithearlierreports
(19–21). In our previous study (1) on the
heritabilityofmetabolicsyndromeandits
individual components, heritability var-
ied from 10.6% (metabolic syndrome) to
42.9%(HDLcholesterol).Theheritability
of plasma adiponectin is higher than the
heritability of metabolic syndrome or of
its individual components, making it an
attractive trait for genome-wide associa-
tion (GWA) studies.
We did not ﬁnd evidence for a sex-
speciﬁc genetic component for plasma
adiponectin (1,13). Patel et al. (18) stud-
ied the genetic correlation between
plasma adiponectin and obesity traits in a
large longitudinal family-based cohort
and found that the genetic correlation
(	G) of plasma adiponectin with BMI and
waist circumference was for both
40%. This result matches well with
our estimate of the genetic correlation be-
tween adiponectin and BMI of 32.4%
using sex, age, and BMI as covariates
(model A). Furthermore, we found, using
model A, a high and signiﬁcant shared
genetic component between plasma adi-
ponectin and the metabolic syndrome
(42.7%). Moreover, this genetic corre-
lation was twice as large as the environ-
mental correlation. Furthermore,
according to model A, waist circumfer-
ence (20.4%), HDL cholesterol
(24.7%), and plasma insulin (20.0%)
shared a signiﬁcant genetic component
Table 2—Genetic and environmental correlation of plasma adiponectin with metabolic syn-
drome, metabolic syndrome components, and metabolic syndrome–related traits
	G SEM P 	E SEM P*
Model A
Metabolic syndrome and its individual components
Metabolic syndrome 42.7 11.3 10
04 19.4 9.4 0.04
Waist circumference 20.4 7.3 10
03 18.8 5.8 10
04
Glucose 2.6 8.7 0.76 12.0 5.6 0.03
HDL cholesterol 24.7 7.2 10
04 35.6 5.5 10
9
Triglycerides 12.2 8.9 0.17 26.0 5.2 10
6
SBP 10.3 9.1 0.26 7.1 5.3 0.18
DBP 9.5 9.2 0.31 6.0 5.4 0.27
Metabolic syndrome–related traits
BMI† 32.4 7.2 10
05 20.7 5.9 10
04
Insulin 20.0 9.9 0.04 18.8 5.1 10
04
HOMA-IR 18.6 9.9 0.06 19.6 5.1 10
04
CRP 11.6 12.3 0.34 13.4 5.4 0.01
Model B
Metabolic syndrome individual components
Waist circumference 15.0 8.9 0.092 22.6 5.6 10
04
Glucose 0.5 8.9 0.955 11.3 5.5 0.040
HDL cholesterol 15.2 7.7 0.048 37.2 5.4 10
11
Triglycerides 11.9 9.8 0.225 26.0 5.1 10
06
SBP 6.3 9.3 0.498 8.5 5.3 0.100
DBP 7.1 9.6 0.459 4.0 5.3 0.450
Metabolic syndrome–related traits
BMI† 12.9 7.9 0.103 14.6 6.1 0.017
Insulin 19.1 10 0.056 19.1 5.1 10
03
HOMA-IR 16.4 10 0.101 20.4 5.1 10
04
CRP 12.3 11.7 0.293 14.4 5.5 0.009
Data are % unless indicated otherwise. Model A included covariates sex, age, and BMI; model B included
covariates sex, age, and metabolic syndrome. *P values were derived using a 
2 test and covariates sex, age,
and BMI. †Covariates sex and age only.
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of the study parameters are strongly asso-
ciatedwitheachother,wealsostudiedthe
genetic correlations, adjusting for meta-
bolic syndrome (model B). Applying this
conservative model, the genetic correla-
tions found according to model A were
consistent, again revealing the genetic
correlations between plasma adiponectin
and HDL cholesterol and plasma insulin.
Our ﬁndings imply that genetic studies of
plasma adiponectin might also lead to the
identiﬁcation of genes associated with
HDL cholesterol and plasma insulin.
The ADIPOQ gene has been found to
be consistently and signiﬁcantly associ-
ated with plasma adiponectin in genetic
association studies (9,22). To investigate
theroleoftheADIPOQgeneinthegenetic
overlap between plasma adiponectin and
metabolic syndrome traits, we performed
association analysis using 10 ADIPOQ
SNPs. Hivert et al. (9) showed a signiﬁ-
cant association of the ADIPOQ SNP
rs17300539 with plasma adiponectin.
Our study of 10 ADOPOQ SNPs showed
that plasma adiponectin was signiﬁcantly
and consistently associated with 6 ADI-
POQ variants using adjustment for sex,
age, and BMI (model A) or adjustment for
sex, age, and metabolic syndrome (model
B). Moreover, our study of 10 ADOPOQ
SNPs showed that plasma adiponectin
wassigniﬁcantlyandindependentlyasso-
ciated with both ADIPOQ rs17300539
and rs182052 variants. ADIPOQ
rs17300539 is located in the promoter
region of the ADIPOQ gene, whereas
ADIPOQ rs182052 is located in exon 1 of
the ADIPOQ gene. Whether these two
variants are actually causal remains to be
determined. Because our heritability and
association analyses on plasma adiponec-
tin and associated traits are in concert
with ﬁndings of other studies in general
cohorts or other genetically isolated pop-
ulations, it seems unlikely that our ﬁnd-
ings are speciﬁc for the genetically
isolated ERF cohort.
Plasmaadiponectinisstronglyassoci-
ated with metabolic syndrome, obesity,
and, in particular, with plasma insulin
and insulin sensitivity. There is evidence
indicating that insulin directly affects
plasma adiponectin (23–25). Thus, it is
likely that the genetics of plasma adi-
ponectin and insulin overlap. Hivert et al.
(9) reported that rs173766743 was
associated with the incidence of type 2
diabetes. Our analyses showed that
rs17300539 was also associated with
plasma insulin and HOMA, indepen-
dently of plasma adiponectin. We did not
observe any effect on this association us-
ingmetabolicsyndromeinsteadofBMIas
a covariate (data not shown). Because
HOMA-IR is a measure for insulin resis-
tance that reﬂects a pre-diabetic state, we
analyzed the r
2 between ADIPOQ
rs17300539 and rs173766743 in Haplo-
view using CEU HapMap data. This anal-
ysis did not show any evidence of linkage
disequilibrium between these variants
(r
2 
 0). An explanation for this apparent
discrepancy may be the adjustment for
plasma adiponectin levels in our associa-
tion analyses. Whether the association of
rs173766743 with type 2 diabetes is in-
dependentofplasmaadiponectinwasnot
reported. The association of rs17300539
with plasma insulin and HOMA-IR is in-
dependent of plasma adiponectin in our
analyses, which implies a direct effect of
this SNP on plasma insulin and insulin
sensitivity. One possible explanation is
that ADIPOQ rs17300539 is associated
with a functional variation of the adi-
ponectin protein affecting insulin sensi-
tivity independent of plasma levels of the
protein. However, this association would
havetobereplicatedinindependentanal-
yses before further investigation.
In summary, the present study con-
ﬁrms and extends the correlation of
plasmaadiponectinwithHDLcholesterol
and plasma insulin. The high heritability
of plasma adiponectin is promising for
GWAs. The genetics of plasma adiponec-
tin is similar between sexes. The genetics
of plasma adiponectin showed a signiﬁ-
cant and consistent overlap with the ge-
netics of HDL cholesterol and plasma
insulin, which implies that GWAs of
plasma adiponectin might also result in
the detection of genetic variation associ-
ated with HDL cholesterol and plasma
insulin.
Genetic association analyses indi-
cated that ADIPOQ variation is strongly
associated with plasma adiponectin and
also that ADIPOQ rs17300539 is associ-
ated with plasma insulin and HOMA-IR
independently of plasma adiponectin.
These genetic association data are thus in
line with the observed genetic overlap be-
tween plasma adiponectin and plasma
insulin.
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Table 3—Association of variants in and around ADIPOQ with plasma adiponectin
SNP Position n
Alleles
(m/M)
Frequency
(m) Effect (m) SEM P
Model A
rs864265 Pr 1,918 G/T 0.19 0.012 0.023 0.601
rs822387 Pr 1,917 C/T 0.95 0.146 0.040 3.0*10
4
rs17300539 Pr 1,919 A/G 0.95 0.155 0.040 9.3*10
5
rs266729 Pr 1,934 G/C 0.74 0.025 0.021 0.230
rs182052 Ex-1 1,916 A/G 0.68 0.070 0.020 3.0*10
4
rs822396 Ex-1 1,925 A/G 0.22 0.043 0.021 0.049
rs2241766 In-1 1,939 G/T 0.93 0.037 0.036 0.303
rs1501299 Ex-2 1,921 T/G 0.73 0.057 0.021 0.006
rs3774262 Ex-2 1,937 A/G 0.93 0.035 0.036 0.330
rs6773957 3
-UTR 1,914 A/G 0.67 0.061 0.020 0.002
Model B
rs864265 Pr 1,904 G/T 0.19 0.006 0.023 0.788
rs822387 Pr 1,904 C/T 0.95 0.143 0.040 3.6*10
4
rs17300539 Pr 1,905 A/G 0.95 0.166 0.040 2.7*10
5
rs266729 Pr 1,920 G/C 0.74 0.017 0.020 0.400
rs182052 Ex-1 1,902 A/G 0.68 0.066 0.019 6.7*10
4
rs822396 Ex-1 1,911 A/G 0.22 0.043 0.022 0.047
rs2241766 In-1 1,924 G/T 0.93 0.046 0.036 0.202
rs1501299 Ex-2 1,907 T/G 0.73 0.055 0.021 0.007
rs3774262 Ex-2 1,923 A/G 0.93 0.046 0.036 0.200
rs6773957 3
-UTR 1,900 A/G 0.67 0.063 0.020 0.001
Model A included covariates sex, age, and BMI; model B included covariates sex, age, and metabolic
syndrome. *P values based on 
2 test. P values in bold were selected for analysis in a backward linear
regression model and were evaluated on linkage disequilibrium using Haploview (CEU HapMap). Ex, exon;
IN, intron; m, effect allele; Pr, promoter; UTR, untranslated region.
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